The bilateral infusions of AB-1005 were well tolerated, without any SAEs linked to the gene therapy or contrast agent.
AskBio Parkinson’s and MSA Scientific chair Krystof Bankiewicz said: “These early findings are encouraging and show AB-1005 to be well tolerated in this study in patients with mild to moderate Parkinson’s disease.
What could be the cause of restless leg syndrome
Too much C/L
Recording available for NSB4PD webinar with Dr. Sackner-Bernstein on "Why I am optimistic that we might now have a Silver Bullet for PD"
